Message #52 From:
NewsBot Date: March 8, 2007 10:57:00 AM
OSCI News CORRECTED: Webcast Alert: Oscient Pharmaceuticals to Present at Cowen & Company 27th Annual Healthcare Conference
WALTHAM, Mass.--(BUSINESS WIRE)--Oscient Pharmaceuticals Corporation (Nasdaq: OSCI) will participate in the Cowen & Company 27th Annual Healthcare Conference on Thursday, March 15, 2007 in Boston. The Company’s President and CEO, Steven Rauscher, will provide an overview of the Company including details on the recent Canadian launch of FACTIVE® (gemifloxacin mesylate) tablets by Abbott Canada and the market performance of ANTARA®(fenofibrate) capsules and FACTIVE in the U.S.
What:
Oscient Pharmaceuticals at Cowen & Co. 27th Annual
Healthcare Conference
When:
March 15, 2007 at 8:45 a.m. Eastern Time
How:
The webcast will be available through the Company's
An archive of the webcast will also be available for three months.
About Oscient Pharmaceuticals
Oscient Pharmaceuticals Corporation is a commercial-stage biopharmaceutical company marketing two FDA-approved products with its national primary care sales force. ANTARA® (fenofibrate) capsules is indicated for the adjunct treatment of hypercholesterolemia (high blood cholesterol) and hypertriglyceridemia (high triglycerides) in combination with diet. FACTIVE® (gemifloxacin mesylate) tablets is an antibiotic approved for the treatment of acute bacterial exacerbations of chronic bronchitis and community-acquired pneumonia of mild to moderate severity. Oscient also has a novel, late-stage antibiotic candidate, Ramoplanin, under investigation for the treatment of Clostridium difficile-associated disease (CDAD).
For important information regarding the safety and use of ANTARA and FACTIVE, please see the full prescribing information available at www.antararx.com and www.factive.com.
